Sandoz Is Satisfied With US Pegfilgrastim Start
Promising Initial Signs For Ziextenzo
Initial market signals from Sandoz’ US launch of its Ziextenzo pegfilgrastim biosimilar are promising, global Biopharmaceuticals head Pierre Bourdage told Generics Bulletin.
You may also be interested in...
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.
Sandoz has published the results of two studies involving the company’s pegfilgrastim biosimilar and glatiramer acetate generic. For the former, Sandoz observed cost savings could run eventually to tens of millions of dollars per year with patient conversion and expanded access.
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.